|Titre :||Comparative analysis of research into illicit drugs in the European Union. Full report|
|Auteurs :||G. BÜHRINGER ; M. FARRELL ; L. KRAUS ; J. MARSDEN ; T. PFEIFFER-GERSCHEL ; D. PIONTEK ; K. KARACHALIOU ; J. KUNZEL ; G. STILLWELL|
|Type de document :||Rapport|
|Editeur :||Bruxelles : Commission Européenne / European Commission, 2009|
|Format :||507 p.|
|Note générale :||Rapport faisant partie de la documentation de référence pour la conférence de la Commission Européenne "Bridging the research gap in the field of illicit drugs in the EU", Bruxelles, 25 et 25 sept. 2009.|
|Discipline :||SAN (Santé publique / Public health)|
Thésaurus TOXIBASECOMPARAISON ; RECHERCHE ; PRODUIT ILLICITE ; MODELE ; EVALUATION ; PARTENARIAT ; FINANCEMENT
Thésaurus GéographiqueUNION EUROPEENNE
The study was commissioned by the European Commissions Directorate-General for Justice, Freedom and Security (Justice-Liberté-Sécurité; DG JLS) with the following six objectives:
(1) To map the key research areas, research disciplines and recent research trends, covering both drug demand and drug supply reduction, taking into account any important interrelations with related thematic areas (i.e. mental health and addiction, licit substance abuse, etc.).
(2) To map and analyse the capacity, infrastructure and model of coordination of drug-related research in the member states (MS). An analysis of the participation of the national research communities in EU programmes should also be conducted.
(3) To map and analyse the capacity, infrastructure and coordination of illicit drug-related research at European and international level, taking into account the drug-related research activities of the Pompidou Group of the Council of Europe and the World Health Organisation as well as the activities of significant private or semi-private research bodies.
(4) To briefly describe for comparative purposes - the drug-related research trends, capacity, infrastructure and model of coordination in the US, Canada and Australia as well as major research collaborations in the drug field with EU partners.
5) To identify strengths and weaknesses in EU drug-related research as well as gaps in the knowledge infrastructure in this field, always bearing in mind that the focus of this study covers both supply and demand of illicit drugs.
(6) To assess options for strengthening if necessary the drug-related research infrastructure in EU. (Extract of the publication)
|Domaine :||Drogues illicites / Illicit drugs|
|Centre Emetteur :||13 OFDT|